Logo do repositório
 
Publicação

Negative MR4·0 chronic myeloid leukaemia and its possible implications for treatment-free remission

2019Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorCerveira, Nuno
dc.contributor.authorDiamond, Joana
dc.contributor.authorMatos, Sónia
dc.contributor.authorAmorim, Maria L
dc.contributor.authorCoucelo, Margarida
dc.contributor.authorBizarro, Susana
dc.contributor.authorSimões, Ana Teresa
dc.contributor.authorPierdomenico, Francesca
dc.contributor.authorLopes, Mariana
dc.contributor.authorRibeiro, Letícia
dc.contributor.authorCarmo-Fonseca, Maria
dc.contributor.authorGuimarães, José E
dc.contributor.authorAlmeida, António
dc.contributor.authorTeixeira, Manuel R
dc.date.accessioned2021-07-29T14:11:37Z
dc.date.available2021-07-29T14:11:37Z
dc.date.issued2019
dc.description© 2019 British Society for Haematology and John Wiley & Sons Ltd.pt_PT
dc.description.abstractABL1 tyrosine kinase inhibitors (TKI) have dramatically improved the outcome for chronic myeloid leukaemia (CML) patients, resulting in a life expectancy that approaches that of the general population. Nevertheless, lifelong TKI therapy may have consequences, including chronic adverse events that can substantially impact patients’ quality of life, adherence to therapy and treatment success. Recently, several clinical discontinuation trials have demonstrated that 40–60% of chronic phase CML patients (CP-CML) who have achieved a stable deep molecular response (DMR) can stop therapy without relapsing (Breccia & Foà, 2018). Laboratory recommendations for scoring DMR were previously defined as MR4·0 [either detectable disease ⩽0·01% BCR-ABLIS (MR4·0 positive) or undetectable disease in cDNA with 10 000–31 999 ABL1 transcripts or 24 000–76 999 GUSB transcripts (MR4·0 negative)], MR4·5 [either detectable disease ⩽0·0032% BCR-ABLIS (MR4·5 positive) or undetectable disease in cDNA with 32 000–99 999 ABL1 transcripts or 77 000–239 999 GUSB transcripts (MR4·5 negative)], and MR5·0 [either detectable disease ⩽0·001% BCR-ABLIS (MR5·0 positive) or undetectable disease in cDNA with ⩾100 000 ABL1 transcripts or ⩾240 000 GUSB transcripts (MR5·0 negative)] (Cross et al, 2015).pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationBr J Haematol. 2019 Sep;186(6):e181-e184pt_PT
dc.identifier.doi10.1111/bjh.16058pt_PT
dc.identifier.eissn1365-2141
dc.identifier.issn0007-1048
dc.identifier.urihttp://hdl.handle.net/10451/49215
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherJohn Wiley & Sons, Inc.pt_PT
dc.relation.publisherversionhttps://onlinelibrary.wiley.com/journal/13652141pt_PT
dc.subjectChronic myeloid leukaemiapt_PT
dc.subjectTreatment-free remissionpt_PT
dc.subjectMolecular response levelpt_PT
dc.subjectqRT-PCRpt_PT
dc.subjectMR4.0 negativept_PT
dc.titleNegative MR4·0 chronic myeloid leukaemia and its possible implications for treatment-free remissionpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPagee184pt_PT
oaire.citation.issue6pt_PT
oaire.citation.startPagee181pt_PT
oaire.citation.titleBritish Journal of Haematologypt_PT
oaire.citation.volume186pt_PT
person.familyNameCarmo-Fonseca
person.givenNameMaria
person.identifier.ciencia-idB31F-0435-0753
person.identifier.orcid0000-0002-3402-7143
person.identifier.scopus-author-id7007128195
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationf4cae50c-2389-4b6a-8e3a-8fd8e538add0
relation.isAuthorOfPublication.latestForDiscoveryf4cae50c-2389-4b6a-8e3a-8fd8e538add0

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Negative_MR40.pdf
Tamanho:
216.97 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

IMM - Artigos em Revistas Internacionais
FM - Artigos em Revistas Internacionais